Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

Rhythm Pharmaceuticals's Return On Capital Employed Insights

Rhythm Pharmaceuticals (NASDAQ:RYTM) brought in sales totaling $1.50 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 23.09%, resulting in a loss of $52.76 million. Rhythm Pharmaceuticals collected $1.82 million in revenue during Q4, but reported earnings showed a $42.87 million loss.

What Is ROCE?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.